Welcome to our dedicated page for BIO-PATH HOLDINGS news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on BIO-PATH HOLDINGS stock.
Bio-Path Holdings develops targeted nucleic acid drug candidates using its DNAbilize® liposomal delivery and antisense RNAi nanoparticle technology. Its disclosed pipeline includes prexigebersen (BP1001), which targets Grb2 for blood cancers; BP1001-A, a modified prexigebersen candidate studied in solid tumors and metabolic disease models; BP1002, which targets Bcl-2 for blood cancers and solid tumors; and a STAT3 antisense program.
Company news commonly covers clinical and preclinical program updates, obesity and Type 2 diabetes research, acute myeloid leukemia and other oncology studies, patent grants tied to DNAbilize®, financial results, investor presentations, and corporate or operational updates affecting the biotechnology portfolio.
Bio-Path Holdings (NASDAQ:BPTH) reported its Q2 2024 financial results and corporate updates. Key highlights include:
Financial Results:
- Net loss of $1.9 million ($1.16 per share) vs $4.2 million ($10.64 per share) in Q2 2023
- R&D expenses decreased to $1.9 million from $3.1 million in Q2 2023
- G&A expenses remained stable at $1.2 million
- Cash position of $4.0 million as of June 30, 2024
Corporate Developments:
- Presented interim results from Phase 2 study of prexigebersen at ASCO and EHA
- Closed $4.0 million private placement in June
- Advancing clinical programs for blood cancers and solid tumors
Bio-Path Holdings (NASDAQ: BPTH) has announced it will host a live conference call and audio webcast on August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and provide a business overview. The company is developing DNAbilize®, a novel RNAi nanoparticle drug technology administered via intravenous transfusion.
Bio-Path's pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. An IND is expected for BP1003, a STAT3 inhibitor.
Bio-Path Holdings (NASDAQ:BPTH), a biotechnology firm, has provided an update on its clinical programs and expansion plans. The company has made significant progress across multiple cancer studies and has completed the development of oncology molecular biomarkers. Additionally, Bio-Path is preparing preclinical studies for prexigebersen as a potential obesity treatment. The company's clinical development program includes one Phase 2 trial and three Phase 1/1b trials. Key updates include: advancing to the second dose level in a Phase 1/1b trial for BP1001-A, completing the second dose cohort in a Phase 1/1b trial for BP1002, and ongoing enrollment in a Phase 1 trial for BP1002 in refractory/relapsed lymphoma and CLL. Bio-Path has also announced preclinical work for BP1003 targeting STAT3 protein and the potential of prexigebersen for obesity-related cancers. The company’s DNAbilize® platform continues to show promise across multiple indications.
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combination therapy was well-tolerated and demonstrated significant clinical improvements. In Cohort 1, 75% of evaluable newly diagnosed AML patients achieved complete remission (CR), CR with partial recovery (CRh), or CR with incomplete hematologic recovery (CRi). In Cohort 2, 55% of evaluable relapsed/refractory AML patients achieved CR/CRi/CRh. Adverse events included fatigue, anemia, and neutropenia, with severe events like febrile neutropenia and sepsis. Bio-Path plans to continue enrolling up to 98 and 54 patients for Cohorts 1 and 2 respectively.
Bio-Path Holdings (NASDAQ: BPTH) has completed a $4.0 million private placement.
This involved the issuance and sale of 1,809,955 shares of common stock and series A and B warrants to purchase an equal number of shares.
The purchase price was $2.21 per share, with the warrants exercisable immediately at $2.00 per share.
The series A warrants expire in five years, while the series B warrants are short-term and expire in 24 months.
H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds will be used for working capital and general corporate purposes.
Bio-Path Holdings (NASDAQ:BPTH) announced a private placement of $4.0 million, involving the sale of 1,809,955 shares of common stock and accompanying warrants priced at $2.21 per share. The series A warrants and series B warrants will be exercisable at $2.00 per share, with expiration periods of five years and 24 months, respectively. The closing is expected on June 5, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The securities are offered under Section 4(a)(2) and/or Regulation D and are not registered under the Securities Act.
Bio-Path Holdings (NASDAQ:BPTH) presented interim results from its Phase 2 study of prexigebersen (BP1001) at the ASCO Annual Meeting on June 1, 2024. The study involves treating acute myeloid leukemia (AML) patients with a combination of prexigebersen, decitabine, and venetoclax. Data from two cohorts were presented: 31 newly diagnosed patients and 38 relapsed/refractory patients.
In Cohort 1, 75% of evaluable newly diagnosed patients achieved complete or partial remission. In Cohort 2, 55% of evaluable relapsed/refractory patients achieved complete or partial remission. Adverse events were consistent with those typically associated with AML treatments, including fatigue, anemia, and neutropenia. Severe adverse events included febrile neutropenia (26%) and sepsis (5%).
Given these promising interim results, Bio-Path plans to continue patient enrollment to meet study targets. The company's DNAbilize® technology shows potential in developing RNAi nanoparticle drugs for various cancers.
Bio-Path Holdings (NASDAQ:BPTH) announced that interim results from its Phase 2 clinical trial of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) will be presented at the 2024 European Hematology Association (EHA) Congress in Madrid. The data indicates that prexigebersen is well-tolerated and shows compelling efficacy in newly diagnosed and relapsed/refractory AML patients, outperforming frontline therapy. Jorge Cortes, M.D., will present these results on June 14, 2024. Bio-Path develops targeted nucleic acid cancer drugs using its DNAbilize® technology. Their pipeline includes BP1002 for blood cancers and solid tumors and BP1003, for which an IND is expected to be filed.
Bio-Path Holdings (NASDAQ: BPTH) announced that it will present interim data from its Phase 2 clinical trial of prexigebersen for Acute Myeloid Leukemia (AML) at the ASCO Annual Meeting from May 31 - June 4, 2024.
The trial, involving prexigebersen combined with decitabine and venetoclax, showed promising results, demonstrating compelling efficacy and good tolerance in newly diagnosed and refractory/relapsed AML patients.
This presentation aims to highlight the potential of prexigebersen within the oncology community and encourage broader clinical participation.
Details of the presentation include: Title - Interim Safety and Efficacy of BP1001 in a Phase II AML Study, Date - June 1, 2024, Time - 8:00 AM CT, Location - McCormick Place, Abstract Number - 6511.
Bio-Path is also advancing other candidates, BP1001-A and BP1002, for various cancers and plans an IND for BP1003 targeting STAT3.
Bio-Path Holdings (NASDAQ: BPTH) announced its Q1 2024 financial results, marking progress in clinical and corporate milestones. The company strengthened its balance sheet with $3.5 million through share offerings and expanded its global patent portfolio. Key achievements include completing the second dose cohort in its Phase 1/1b trial for BP1002 in AML patients and the first dose cohort for BP1002 in lymphoma and CLL patients.
Financially, Bio-Path reported a net loss of $3.2 million, an improvement from the $5.3 million loss in Q1 2023. R&D expenses decreased to $2.3 million, while G&A expenses slightly increased to $1.4 million. The company had $0.2 million in cash as of March 31, 2024.